Biolipox Interim Report, January - June 2006

* Revenues for the first six months amounted to SEK 22.0 million (0). For the second quarter revenues amounted to SEK 11.0 million (0).

* Earnings after tax for the first six months amounted to SEK -33.5 million (loss: 53.3). For the second quarter earnings after tax amounted to SEK -16.7 million (loss: 28.9).

* Earnings per share for the first six months was SEK -47.35 (loss: 66.33). For the second quarter earnings per share was SEK -23.69 (loss: 35.56).

* Cash flow for the first six months was positive and amounted to SEK 3.6 million (89.5). For the second quarter cash flow was negative and amounted to SEK -13.4 million (negative: 23.7).

* Drug development projects advance according to plan

* Biolipox strengthens the R&D organization


Forthcoming financial information
* Interim report, January - September 2006 19 October 2006


Biolipox’s interim report 1 January – 30 June, 2006 is presented on the following pages.